Logo
Search

Rules:

Only words with 2 or more characters are accepted
Max 200 chars total
Space is used to split words, "" can be used to search for a whole string (not indexed search then)
AND, OR and NOT are prefix words, overruling the default operator
+/|/- equals AND, OR and NOT as operators.
All search words are converted to lowercase.

Search for "cardiac"

Displaying results 1 to 7 out of 7

  Trainings / Workshops 81%
  Trainings / Workshops Workshop In cooperation with iCardiac, CRS is happy to invite you to the upcoming Early Drug Development Workshop: An Alternative to the Thorough QT Trial-EPQT, An International ...
  Size: 30 K - Created: 04-09-13 - Modified: 20-06-17 17:09
Path: /CRS/Trainings / Workshops

  News 4 74%
  ... that logistical processes run as smoothly as possible. Assumptions: Monoclonal antibody (mAB) for an oncological treatment Known critical cardiac safety profile according to the SMPC Clinical conduct in 6 months with more than 100 healthy subjects IMP preparation & labelling immediately prior to dosing under GMP conditions Integration of external specialists (cardiologists) for
  Size: 30 K - Created: 18-11-12 - Modified: 20-06-17 17:09
Path: /Home/News 4

  Partners 69%
  ... and archive of clinical research data and metadata. iCardiac www.icardiac.com Services iCardiac Technologies, Inc. is an industry-leading centralised core laboratory for cardiac safety and respiratory services.  Its high precision cardiac safety assessment methodology has set a new standard ...
  Size: 44 K - Created: 18-11-12 - Modified: 20-06-17 17:09
Path: /CRS/Partners

  Trial Expertise 67%
  ... the availability of pre-clinical and clinical data on the molecule. Cardiac safety trials in healthy subjects and patients About 3–5 trials annually are cardiac safety trials. In some cases CRS cooperates with a central ECG ... CRS has access to a broad range of genotyped subjects . Thorough QTc/
  Size: 35 K - Created: 18-11-12 - Modified: 20-06-17 17:09
Path: /Expertise/Trial Expertise

  1981 – 1989 47%
  ... 23-28 July 1989. Euro J Clin Pharmacol 36: (Suppl.): A136, PP02.07; 1989 . Kirch W, Halabi A , Ohnhaus EE. Negative effects of famotidine on cardiac performance assessed by non-invasive hemodynamic measurements. Gastroenterology 1989 ; 96: 1388-1393. Kirch W, Nokhodian A, Halabi A , Linde M, ...
  Size: 42 K - Created: 18-11-12 - Modified: 20-06-17 17:09
Path: /Expertise/Published Expertise/1981 – 1989

  2000 – 2009 46%
  ... of first-to-human trials). Lecture at the 10th Annual Congress of Clinical Pharmacology (VkliPha 2008), November 6-8, 2008, Berlin. Timmer W. Cardiac Safety – Dr Wolfgang Timmer of CRS examines the conduct of thorough QTc trials in practice from a Phase I CRO's perspective. European ... Congress on Phytomedicine, Munich, Germany, 11-13 October 2000 . M Bindschedler, G Lefèvre, F Ezzet, N Schaeffer , I Meyer , M S Thomsen.
  Size: 53 K - Created: 09-11-15 - Modified: 20-06-17 17:09
Path: /Expertise/Published Expertise/2000 – 2009

  1990 – 1999 44%
  ... of Clinical Pharmacology 1993 ; 35: 461-466. Mescheder A, Ebert U, Halabi A , Kirch W. Changes in the effects of nizatidine and famotidine on cardiac performance after pretreatment with ranitidine. European Journal of Clinical Pharmacology 1993 ; 45 (2): 151-156. Mescheder A, Halabi A , Nokhodian A, Al-Hamdan Y, Kirch W. Antihypertensive activity,
  Size: 61 K - Created: 18-11-12 - Modified: 20-06-17 17:09
Path: /Expertise/Published Expertise/1990 – 1999

FooterEnd